Table of Contents
This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Inc’s Xalkori for non-small cell lung cancer, Novartis' halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roche's acquisition of IQuum's Liat Analyzer, and Bio-Rad's acquisition of GnuBio.
Deals, a Joint Venture and a Mega Deal Brewing….
Novartis to Buy Glaxo Cancer Drugs; Joint Venture Between Glaxo and Novartis for Consumer Products; Eli Lilly’s Elanco Snags Novartis’s Animal Health Unit in $5.4 Billion Deal; AstraZeneca Cancer Pipeline Seen as Draw for Pfizer.
Get Industry Insights. Simply.
Talk to Amrita
+1 718 303 2019
The lung cancer surgery market is projected to reach USD 29.99 billion by 2021 from USD 21.58 billion in 2016, at a CAGR of 6.8% from 2016 to 2021. The global lung cancer surgery market is segmented based ...
Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...
“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics ...